Background The global surge in the omicron (B. 1.1. 529) variant has resulted in many
individuals with hybrid immunity (immunity developed through a combination of SARS-CoV …

Background Understanding the level and characteristics of protection from past SARS-CoV-
2 infection against subsequent re-infection, symptomatic COVID-19 disease, and severe …

Background Synthesising evidence on the long-term vaccine effectiveness of COVID-19
vaccines (BNT162b2 [Pfizer–BioNTech], mRNA-1273 [Moderna], ChAdOx1 nCoV-19 …

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract
infection in children younger than 5 years. In 2019, a meta-analysis estimated that RSV was …

Real-world data on the effectiveness of COVID-19 vaccines against the Omicron variant (B.
1.1. 529) is limited. This systematic review aimed to investigate the real-world effectiveness …

Abstract A Gamma Variant RBD-based aluminum hydroxide adjuvanted vaccine called
ARVAC CG was selected for a first in human clinical trial. Healthy male and female …

Coronaviruses are important human and animal pathogens. At the end of 2019, a novel
coronavirus was identified as the cause of a cluster of pneumonia cases in Wuhan, a city in …

Objective: To study SARS-CoV-2 reinfections in health-care workers (HCWs) of the
University Health Agency Giuliano-Isontina (ASUGI), covering the provinces of Trieste and …

Since April, 2022, BA. 2.12. 1, BA. 4, and BA. 5 subvariants of the omicron (B. 1.1. 529)
SARS-CoV-2 variant of concern have been spreading globally with increased viral fitness …

SARS-CoV-2 reinfections increased substantially after Omicron variants emerged. Large-
scale community-based comparisons across multiple Omicron waves of reinfection …